Top-line phase 2b study results
Stockholm 8th September, 2015. – The Board of Peptonic Medical (publ) - a company developing pharmaceuticals based on oxytocin – today announced that it has reviewed the un-blinded clinical data of the phase 2b study of Vagitocin® (oxytocin) in the treatment of Vaginal Atrophy in post-menopausal women.The study did not meet its clinical endpoints, because all treatment groups, including the placebo, showed the same statistically significant improvement in both subjective and objective parameters. The board cannot explain how placebo can have an equal positive effect as active drug, and